LivaNova (NASDAQ:LIVN) Rating Increased to Buy at StockNews.com

LivaNova (NASDAQ:LIVNGet Rating) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Friday.

A number of other equities analysts have also recently commented on LIVN. Needham & Company LLC reduced their price objective on shares of LivaNova from $106.00 to $88.00 and set a “buy” rating for the company in a research report on Thursday, August 4th. The Goldman Sachs Group decreased their price target on shares of LivaNova from $85.00 to $73.00 and set a “buy” rating on the stock in a research note on Tuesday, August 16th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, LivaNova presently has a consensus rating of “Buy” and an average price target of $90.20.

LivaNova Stock Up 2.2 %

Shares of LIVN stock opened at $57.72 on Friday. LivaNova has a 52-week low of $53.28 and a 52-week high of $93.89. The stock has a market cap of $3.08 billion, a price-to-earnings ratio of -103.07 and a beta of 0.91. The firm’s 50-day moving average is $61.25 and its 200-day moving average is $68.66. The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.47 and a current ratio of 2.93.

LivaNova (NASDAQ:LIVNGet Rating) last released its quarterly earnings data on Wednesday, August 3rd. The company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.51 by $0.02. LivaNova had a positive return on equity of 9.35% and a negative net margin of 2.74%. The firm had revenue of $254.20 million for the quarter, compared to analyst estimates of $249.55 million. During the same quarter in the prior year, the company earned $0.52 earnings per share. The business’s revenue for the quarter was down 3.9% compared to the same quarter last year. Sell-side analysts predict that LivaNova will post 1.91 EPS for the current year.

Hedge Funds Weigh In On LivaNova

Several institutional investors and hedge funds have recently modified their holdings of the business. Legal & General Group Plc raised its stake in LivaNova by 1.7% in the 2nd quarter. Legal & General Group Plc now owns 132,036 shares of the company’s stock worth $8,248,000 after purchasing an additional 2,187 shares in the last quarter. Nomura Holdings Inc. acquired a new position in LivaNova in the 2nd quarter valued at $897,000. Price T Rowe Associates Inc. MD lifted its position in shares of LivaNova by 1.1% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 28,970 shares of the company’s stock valued at $1,810,000 after acquiring an additional 308 shares during the period. State Street Corp grew its holdings in shares of LivaNova by 0.8% during the 2nd quarter. State Street Corp now owns 2,393,881 shares of the company’s stock worth $149,546,000 after purchasing an additional 18,634 shares in the last quarter. Finally, Clearline Capital LP bought a new position in shares of LivaNova in the second quarter worth $438,000. 98.89% of the stock is currently owned by institutional investors and hedge funds.

About LivaNova

(Get Rating)

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

Featured Stories

Analyst Recommendations for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.